David P. Meeker - 18 Mar 2026 Form 3 Insider Report for Pharvaris N.V. (PHVS)

Reporting relationship: Director
Issuer ticker: PHVS
Reported as of: 18 Mar 2026
Net transaction value: $0
SEC form: 3
Accepted by SEC: 18 Mar 2026, 14:23:23 UTC
Prior SEC filing: 13 Feb 2026
Next SEC filing: 04 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Marnus Nel, Attorney-in-Fact for David Meeker

Key filing fact

David P. Meeker filed Form 3 for Pharvaris N.V. (PHVS) on 18 Mar 2026.

Key facts

This page summarizes David P. Meeker's Form 3 filing for Pharvaris N.V. (PHVS).
0 reported transactions and 6 derivative rows are listed below.
Accepted by SEC: 18 Mar 2026, 14:23.

Change

Previous filing in this sequence was filed on 13 Feb 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0001385155 Primary reporting owner

Meeker David P

Relationship: Director
Address: 1 CRANBERRY HILL SUITE 400, LEXINGTON
Signature: /s/ Marnus Nel, Attorney-in-Fact for David Meeker
Signature date: 18 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

PHVS holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 65,167
Date: 18 Mar 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PHVS holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 18 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 16,500
Exercise price: $28.00
Footnotes: F2

PHVS holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 18 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 15,000
Exercise price: $16.05
Footnotes: F2

PHVS holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 18 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 14,000
Exercise price: $22.31
Footnotes: F2

PHVS holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 18 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 21,000
Exercise price: $8.05
Footnotes: F3

PHVS holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 18 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 17,500
Exercise price: $18.14
Footnotes: F4

PHVS holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 18 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 80,000
Exercise price: $7.89
Footnotes: F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

Includes restricted stock units previously granted under the Company's equity plan that remain outstanding as of March 18, 2026. The awards settle in shares of common stock and are reported in Table I as non-derivative securities. Vesting occurs as follows: -5,500 RSUs from an award granted March 3, 2026 of which 100% will vest March 3, 2027.

Footnote F2

100% of the option vest on the 12-month anniversary.

Footnote F3

25% of the option vested on April 6, 2024 with the remaining shares vesting in 1/48 monthly installments thereafter.

Footnote F4

25% of the option vested on April 1, 2023 with the remaining shares vesting in 1/48 monthly installments thereafter.

Footnote F5

25% of the option vested on January 1, 2022 with the remaining shares vesting in 1/48 monthly installments thereafter.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .